ATE483729T1 - Peptid - Google Patents

Peptid

Info

Publication number
ATE483729T1
ATE483729T1 AT08002817T AT08002817T ATE483729T1 AT E483729 T1 ATE483729 T1 AT E483729T1 AT 08002817 T AT08002817 T AT 08002817T AT 08002817 T AT08002817 T AT 08002817T AT E483729 T1 ATE483729 T1 AT E483729T1
Authority
AT
Austria
Prior art keywords
peptide
mbp
peptides
molecule
prevention
Prior art date
Application number
AT08002817T
Other languages
English (en)
Inventor
David Cameron Wraith
Stephen Mark Anderton
Graziella Mazza
Mary Ponsford
Heather Barbara Streeter
Original Assignee
Apitope Technology Bristol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE483729(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0020618A external-priority patent/GB0020618D0/en
Priority claimed from GB0114547A external-priority patent/GB0114547D0/en
Application filed by Apitope Technology Bristol Ltd filed Critical Apitope Technology Bristol Ltd
Application granted granted Critical
Publication of ATE483729T1 publication Critical patent/ATE483729T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
AT08002817T 2000-08-21 2001-08-17 Peptid ATE483729T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0020618A GB0020618D0 (en) 2000-08-21 2000-08-21 Peptide selection method
GB0114547A GB0114547D0 (en) 2001-06-14 2001-06-14 Peptide selection method

Publications (1)

Publication Number Publication Date
ATE483729T1 true ATE483729T1 (de) 2010-10-15

Family

ID=26244875

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08002817T ATE483729T1 (de) 2000-08-21 2001-08-17 Peptid
AT01956718T ATE401343T1 (de) 2000-08-21 2001-08-17 Tolerogenische peptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01956718T ATE401343T1 (de) 2000-08-21 2001-08-17 Tolerogenische peptide

Country Status (25)

Country Link
US (4) US20030191063A1 (de)
EP (3) EP1311542B1 (de)
JP (1) JP5431628B2 (de)
KR (1) KR20030062321A (de)
CN (4) CN1469883A (de)
AT (2) ATE483729T1 (de)
AU (2) AU7863701A (de)
BR (2) BRPI0113400B1 (de)
CA (1) CA2420949C (de)
CY (3) CY1108558T1 (de)
CZ (1) CZ307202B6 (de)
DE (2) DE60134862D1 (de)
DK (3) DK1918298T3 (de)
ES (3) ES2310558T3 (de)
HK (3) HK1052359B (de)
HU (3) HU230233B1 (de)
IL (1) IL154089A0 (de)
MX (1) MXPA03001606A (de)
NO (2) NO330535B1 (de)
NZ (1) NZ523841A (de)
PH (1) PH12013500208B1 (de)
PL (4) PL217929B1 (de)
PT (3) PT1731912E (de)
SI (3) SI1918298T1 (de)
WO (1) WO2002016410A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191063A1 (en) 2000-08-21 2003-10-09 Wraith David Cameron Peptide selection method
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
PT2420833E (pt) * 2006-05-05 2015-11-24 Opexa Therapeutics Vacina de células t
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
KR101699554B1 (ko) 2007-08-15 2017-01-25 서카시아 리미티드 백신용 펩티드
CN101848725B (zh) * 2007-10-31 2013-05-22 艾匹托普技术(布里斯托尔)有限公司 组合物
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
ITMI20080508A1 (it) * 2008-03-27 2009-09-28 Istituto Nazionale Di Genetica Molecolare Cellule ematopoietiche esprimenti la proteina krtcap3 e i leganti per la proteina krtcap3
ITMI20080865A1 (it) * 2008-05-13 2009-11-14 Istituto Naz Di Genetica Molecolare Ingm Cellule ematopoietiche esprimenti la proteina susd3 e i leganti per la proteina susd3
US9085798B2 (en) 2009-04-30 2015-07-21 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
EA024832B1 (ru) 2009-10-12 2016-10-31 ЛАЙФБИО ЛАБОРАТОРИС ЭлЭлСи Олигопептид, связывающий гидролизующие аутоантитела к основному белку миелина mbp, композиции и способ лечения рассеянного склероза
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
PL2556171T3 (pl) 2010-04-05 2016-04-29 Prognosys Biosciences Inc Oznaczenia biologiczne kodowane przestrzennie
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
KR200457779Y1 (ko) * 2010-06-23 2012-01-06 이준혁 샤프펜슬
US20120258871A1 (en) 2011-04-08 2012-10-11 Prognosys Biosciences, Inc. Peptide constructs and assay systems
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
PL397623A1 (pl) * 2011-12-30 2013-07-08 Napco S. Ar.L. Preparat poprawiajacy pamiec oraz uczenie sie, sposób jego wytwarzania, srodek farmaceutyczny, dodatek zywieniowy oraz jego zastosowanie
LT2917232T (lt) 2012-11-12 2017-06-26 Apitope International Nv Iš faktoriaus vii kilę peptidai, skirti naudoti hemofilijos gydymui
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN105358984B (zh) * 2013-03-15 2020-02-18 普罗格诺西斯生物科学公司 用于检测肽/mhc/tcr结合的方法
CN118240918A (zh) 2013-06-25 2024-06-25 普罗格诺西斯生物科学公司 采用微流控装置的空间编码生物分析
GB201314052D0 (en) * 2013-08-06 2013-09-18 Apitope Int Nv Peptides
WO2015070037A2 (en) 2013-11-08 2015-05-14 Prognosys Biosciences, Inc. Polynucleotide conjugates and methods for analyte detection
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
KR102585625B1 (ko) * 2014-12-24 2023-10-05 아피토프 인터내셔날 엔브이 조성물
EP4119677B1 (de) 2015-04-10 2023-06-28 Spatial Transcriptomics AB Räumlich getrennte multiplex-nukleinsäureanalyse von biologischen proben
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
AU2018206358B2 (en) * 2017-01-04 2021-05-27 Worg Pharmaceuticals (Zhejiang) Co., Ltd. S-Arrestin peptides and therapeutic uses thereof
US20200046802A1 (en) * 2017-01-04 2020-02-13 Apitope International Nv Therapeutic method using tolerogenic peptides
ES2905890T3 (es) 2017-01-06 2022-04-12 Eutilex Co Ltd Anticuerpos anti-4-1BB humano y usos de los mismos
GB201909774D0 (en) 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method
RU2761617C2 (ru) * 2019-10-04 2021-12-13 Жаудат Гафурович Умеров Комплекс липидов миелина центральной и периферической нервной системы животных для лечения и профилактики нейродегенеративных демиелинизирующих нарушений и способы его применения
GB201919222D0 (en) 2019-12-23 2020-02-05 Apitope Int Nv Composition
TR201922305A2 (tr) * 2019-12-30 2021-07-26 T C Erciyes Ueniversitesi Multi̇pl skleroz (ms) hastaliğinda beta-kazomorfi̇n pepti̇tleri̇ni̇n kullanilmasi
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
CA3182369A1 (en) 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
EP4153775A1 (de) 2020-05-22 2023-03-29 10X Genomics, Inc. Simultane räumlich-zeitliche messung der genexpression und der zellaktivität

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327162C (en) 1987-04-09 1994-02-22 Board Of Trustees Of The Leland Stanford Junior University (The) Method for prophylactically treating an individual for an autoimmune disease
JP2512796B2 (ja) 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド 自己抗原の経口投与による自己免疫疾患の治療法
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5989565A (en) 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
SK145896A3 (en) * 1994-05-10 1997-05-07 Immulogic Pharma Corp Medicaments containing therapeutically effective quantity of antigen peptid of human mbp and ifn-beta
AU7242994A (en) 1994-05-20 1995-12-18 United States Of America, As Represented By The Secretary Of The Army, The Model for testing immunogenicity of peptides
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6251396B1 (en) * 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6379670B1 (en) * 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
EP0825870A4 (de) * 1995-04-20 2002-09-25 Brigham & Womens Hospital Modulierung von cytokin-mustern von menschlichen t-zell klonen
DE69723434T2 (de) * 1996-04-26 2004-05-19 Rijksuniversiteit Te Leiden Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
EP0849275A1 (de) * 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Mannosylierte Peptide
EP1085892A4 (de) 1998-06-12 2002-07-17 Sloan Kettering Inst Cancer Impfstrategie zur vorbeugung und behandlung von krebs
MY129566A (en) * 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
US20030191063A1 (en) * 2000-08-21 2003-10-09 Wraith David Cameron Peptide selection method
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
US8314290B2 (en) 2004-12-21 2012-11-20 Monsanto Technology Llc Temporal regulation of gene expression by MicroRNAs
CN101848725B (zh) 2007-10-31 2013-05-22 艾匹托普技术(布里斯托尔)有限公司 组合物
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides

Also Published As

Publication number Publication date
DE60143234D1 (de) 2010-11-18
ES2310558T3 (es) 2009-01-16
DK1731912T3 (da) 2014-01-06
PL217929B1 (pl) 2014-09-30
MXPA03001606A (es) 2004-11-01
EP1731912A3 (de) 2006-12-27
PT1311542E (pt) 2008-10-03
ES2439899T3 (es) 2014-01-27
SI1731912T1 (sl) 2014-05-30
EP1311542B1 (de) 2008-07-16
AU7863701A (en) 2002-03-04
HK1052359A1 (en) 2003-09-11
CY1108558T1 (el) 2014-04-09
AU2001278637B2 (en) 2006-05-25
EP1731912A2 (de) 2006-12-13
EP1311542A2 (de) 2003-05-21
BR0113400A (pt) 2003-07-08
DK1311542T3 (da) 2008-11-10
NO20030790D0 (no) 2003-02-19
US20080200368A1 (en) 2008-08-21
CN102784385B (zh) 2015-11-25
PL399137A1 (pl) 2012-07-30
PH12013500208A1 (en) 2015-04-20
PL215187B1 (pl) 2013-11-29
BRPI0113400B1 (pt) 2018-05-15
CN102764425B (zh) 2015-11-25
HK1178793A1 (en) 2013-09-19
HU230233B1 (hu) 2015-10-28
NO20030790L (no) 2003-04-22
EP1731912B1 (de) 2013-09-25
NO330535B1 (no) 2011-05-09
CN102764425A (zh) 2012-11-07
KR20030062321A (ko) 2003-07-23
PL215145B1 (pl) 2013-10-31
PT1918298E (pt) 2010-12-09
JP2004506921A (ja) 2004-03-04
WO2002016410A3 (en) 2002-09-12
NZ523841A (en) 2004-07-30
EP1918298A3 (de) 2008-05-28
DE60134862D1 (de) 2008-08-28
PH12013500208B1 (en) 2015-04-20
US20130156798A1 (en) 2013-06-20
PL364048A1 (en) 2004-12-13
PL399138A1 (pl) 2012-07-30
CN102784385A (zh) 2012-11-21
CZ307202B6 (cs) 2018-03-21
DK1918298T3 (da) 2010-11-29
HK1052359B (zh) 2008-11-14
HU229377B1 (hu) 2013-11-28
CY1114808T1 (el) 2016-12-14
NO20101441L (no) 2003-04-22
JP5431628B2 (ja) 2014-03-05
HUP0300814A2 (hu) 2003-10-28
EP1918298A2 (de) 2008-05-07
IL154089A0 (en) 2003-07-31
PL213585B1 (pl) 2013-03-29
CN101633689A (zh) 2010-01-27
CA2420949A1 (en) 2002-02-28
ATE401343T1 (de) 2008-08-15
SI1311542T1 (sl) 2009-02-28
WO2002016410A2 (en) 2002-02-28
US20030191063A1 (en) 2003-10-09
PT1731912E (pt) 2013-12-17
CA2420949C (en) 2012-01-03
CY1111079T1 (el) 2015-06-11
US20180311328A1 (en) 2018-11-01
US8961986B2 (en) 2015-02-24
ES2353347T3 (es) 2011-03-01
CN1469883A (zh) 2004-01-21
NO337988B1 (no) 2016-07-18
SI1918298T1 (sl) 2011-01-31
US8343500B2 (en) 2013-01-01
CN101633689B (zh) 2013-09-04
HUP0300814A3 (en) 2005-11-28
EP1918298B1 (de) 2010-10-06
HK1178437A1 (en) 2013-09-13
HU229489B1 (hu) 2014-01-28

Similar Documents

Publication Publication Date Title
ATE483729T1 (de) Peptid
AU2002229510A1 (en) Combined use of factor vii polypeptides and factor viii polypeptides
MY129566A (en) A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
DE60333728D1 (de) Tolerogene peptide des basischen myelinproteins
DK1429800T3 (da) Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose
FI941860A (fi) Keskushermoston pesäkekovettumatautiaivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin synteettinen peptidispesifisyys
DK0759772T3 (da) Tri-, tetra-, penta- og polypeptider og deres terapeutiske anvendelse som antidepressiva
EE200000478A (et) Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
HUP0401121A2 (hu) Csökkentett immunogenitású, módosított trombopoietin (TPO)
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
HUP0402160A2 (hu) T-sejt-epitópok a karboxipeptidáz-G2-ben
ES2183376T3 (es) Uso de lbp para el tratamiento de la septicemia.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1918298

Country of ref document: EP